Rolvedon

Active Ingredient(s): Eflapegrastim-xnst
FDA Approved: * September 9, 2022
Pharm Company: * SPECTRUM PHARMS
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rolvedon 13.2 mg/.6ml Subcutaneous Injection, Solution
NDC: 76961-101
Labeler:
Spectrum Pharmaceuticals, Inc.
Rolvedon 13.2 mg/.6ml Subcutaneous Injection, Solution
NDC: 82497-132
Labeler:
Assertio Specialty Pharmaceuticals, LLC